BioStock: Curasight ready to move forward in brain cancer

So far Danish Curasight has seen positive phase II results in three out of its four strategic target indications with its uTRACE drug candidate. The time has now come to the phase II study within the main strategic indication, brain cancer. The investigator-initiated study has now been fully recruited and the company expects results to be published during the second half this year.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/07/curasight-ready-to-move-forward-in-brain-cancer/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se